| 2025-12-05 |
详情>>
内部人交易：
KIIL HARRY SKIP股份减少1702.00股
|
| 2025-11-25 |
详情>>
股本变动：
变动后总股本128201.42万股
|
| 2025-11-25 |
详情>>
业绩披露：
2026年中报每股收益1.88美元,归母净利润24.14亿美元,同比去年增长4.41%
|
| 2025-11-18 |
财报披露：
美东时间 2025-11-18 盘后发布财报
|
| 2025-08-26 |
详情>>
业绩披露：
2026年一季报每股收益0.81美元,归母净利润10.40亿美元,同比去年增长-0.19%
|
| 2025-08-25 |
股东大会：
将于2025-10-16召开股东大会
会议内容 ▼▲
- 1.Electing, by separate resolutions, the twelve director nominees named in the proxy statement to hold office until the 2026 Annual General Meeting of Medtronic plc (the “Company”);
2.Ratifying, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the Company’s independent auditor for fiscal year 2026 and authorizing, in a binding vote, the Board of Directors, acting through the Audit Committee, to set the auditor’s remuneration;
3.Approving, on an advisory basis, the Company’s executive compensation;
4.Renewing the Board of Directors’ authority to issue shares under Irish law;
5.Renewing the Board of Directors’ authority to opt out of pre-emption rights under Irish law;
6.Authorizing the Company and any subsidiary of the Company to make overseas market purchases of Medtronic ordinary shares;
7.Approving an amendment to Article 177 of the Company’s Articles of Association to facilitate the capitalization of certain of the Company’s non-distributable reserves;
8.Approving a Capital Reduction to Create Distributable Reserves under Irish Law;
9.Approving amendments to the Company’s Articles of Association to update the advance notice provisions;
10.Receiving and considering the Company’s Irish Statutory Financial Statements for the fiscal year ended April 25, 2025 and the reports of the directors and auditors thereon, and reviewing the affairs of the Company;
11.Transacting any other business that may properly come before the meeting and any adjournments or postponements thereof.
|
| 2025-06-20 |
详情>>
业绩披露：
2023年年报每股收益2.83美元,归母净利润37.58亿美元,同比去年增长-25.42%
|
| 2025-06-20 |
详情>>
业绩披露：
2025年年报每股收益3.63美元,归母净利润46.62亿美元,同比去年增长26.82%
|
| 2025-02-25 |
详情>>
业绩披露：
2025年三季报(累计)每股收益2.80美元,归母净利润36.06亿美元,同比去年增长19.32%
|
| 2024-11-26 |
详情>>
业绩披露：
2025年中报每股收益1.79美元,归母净利润23.12亿美元,同比去年增长36.00%
|
| 2024-08-27 |
详情>>
业绩披露：
2025年一季报每股收益0.81美元,归母净利润10.42亿美元,同比去年增长31.73%
|
| 2024-08-27 |
详情>>
业绩披露：
2024年一季报每股收益0.59美元,归母净利润7.91亿美元,同比去年增长-14.85%
|
| 2024-08-09 |
股东大会：
将于2024-10-17召开股东大会
会议内容 ▼▲
- 1.Electing, by separate resolutions, the ten director nominees named in the proxy statement to hold office until the 2025 Annual General Meeting of Medtronic plc (the “Company”);
2.Ratifying, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the Company’s independent auditor for fiscal year 2025 and authorizing, in a binding vote, the Board of Directors, acting through the Audit Committee, to set the auditor’s remuneration;
3.Approving, on an advisory basis, the Company’s executive compensation;
4.Renewing the Board of Directors’ authority to issue shares under Irish law;
5.Renewing the Board of Directors’ authority to opt out of pre-emption rights under Irish law;
6.Authorizing the Company and any subsidiary of the Company to make overseas market purchases of Medtronic ordinary shares;
7.Receiving and considering the Company’s Irish Statutory Financial Statements for the fiscal year ended April 26, 2024 and the reports of the directors and auditors thereon, and reviewing the affairs of the Company;
8.Transacting any other business that may properly come before the meeting and any adjournments or postponements thereof.
|
| 2024-06-20 |
详情>>
业绩披露：
2024年年报每股收益2.77美元,归母净利润36.76亿美元,同比去年增长-2.18%
|
| 2024-02-27 |
详情>>
业绩披露：
2024年三季报(累计)每股收益2.27美元,归母净利润30.22亿美元,同比去年增长17.18%
|
| 2023-11-30 |
详情>>
业绩披露：
2024年中报每股收益1.28美元,归母净利润17.00亿美元,同比去年增长25.37%
|
| 2023-08-11 |
股东大会：
将于2023-10-19召开股东大会
会议内容 ▼▲
- 1.Electing, by separate resolutions, the eleven director nominees named in the proxy statement to hold office until the 2024 Annual General Meeting of Medtronic plc (the “Company”);
2.Ratifying, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the Company’s independent auditor for fiscal year 2024 and authorizing, in a binding vote, the Board of Directors, acting through the Audit Committee, to set the auditor’s remuneration;
3.Approving, on an advisory basis, the Company’s executive compensation;
4.Approving the Company’s 2024 Employee Stock Purchase Plan;
5.Renewing the Board of Directors’ authority to issue shares under Irish law;
6.Renewing the Board of Directors’ authority to opt out of pre-emption rights under Irish law;
|
| 2023-08-11 |
股东大会：
将于2023-10-19召开股东大会
会议内容 ▼▲
- 1.Electing, by separate resolutions, the eleven director nominees named in the proxy statement to hold office until the 2024 Annual General Meeting of Medtronic plc (the “Company”);
2.Ratifying, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the Company’s independent auditor for fiscal year 2024 and authorizing, in a binding vote, the Board of Directors, acting through the Audit Committee, to set the auditor’s remuneration;
3.Approving, on an advisory basis, the Company’s executive compensation;
4.Approving the Company’s 2024 Employee Stock Purchase Plan;
5.Renewing the Board of Directors’ authority to issue shares under Irish law;
6.Renewing the Board of Directors’ authority to opt out of pre-emption rights under Irish law;
|
| 2022-08-19 |
股东大会：
将于2022-12-08召开股东大会
会议内容 ▼▲
- 1.Electing, by separate resolutions, the eleven director nominees named in the proxy statement to hold office until the 2023 Annual General Meeting of Medtronic plc (the “Company”);
2.Ratifying, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the Company’s independent auditor for fiscal year 2023 and authorizing, in a binding vote, the Board of Directors, acting through the Audit Committee, to set the auditor’s remuneration;
3.Approving, on an advisory basis, the Company’s executive compensation;
4.Renewing the Board of Directors’ authority to issue shares under Irish law;
5.Renewing the Board of Directors’ authority to opt out of pre-emption rights under Irish law;
6.Authorizing the Company and any subsidiary of the Company to make overseas market purchases of Medtronic ordinary shares;
7.Receiving and considering the Company’s Irish Statutory Financial Statements for the fiscal year ended April 29, 2022 and the reports of the directors and auditors thereon, and reviewing the affairs of the Company;
8.Transacting any other business that may properly come before the meeting.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-08-27 |
股东大会：
将于2021-12-09召开股东大会
会议内容 ▼▲
- 1.Electing, by separate resolutions, the ten director nominees named in the proxy statement to hold office until the 2022 Annual General Meeting of Medtronic plc (the “Company”);
2.Ratifying, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the Company’s independent auditor for fiscal year 2022 and authorizing, in a binding vote, the Board of Directors, acting through the Audit Committee, to set the auditor’s remuneration;
3.Approving, on an advisory basis, the Company’s executive compensation;
4.Approving, on an advisory basis, the frequency of Say-on-Pay votes;
5.Approving the new 2021 Medtronic plc Long Term Incentive Plan;
6.Renewing the Board of Directors’ authority to issue shares under Irish law;
7.Renewing the Board of Directors’ authority to opt out of pre-emption rights under Irish law;
8.Authorizing the Company and any subsidiary of the Company to make overseas market purchases of Medtronic ordinary shares;
9.Receiving and considering the Company’s Irish Statutory Financial Statements for the fiscal year ended April 30, 2021 and the reports of the directors and auditors thereon, and reviewing the affairs of the Company;
10.Transacting any other business that may properly come before the meeting.
|
| 2020-10-13 |
股东大会：
将于2020-12-11召开股东大会
会议内容 ▼▲
- 1.Electing, by separate resolutions, the twelve director nominees named in the proxy statement to hold office until the 2021 Annual General Meeting of the Company;
2.Ratifying, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the Company’s independent auditor for fiscal year 2021 and authorizing, in a binding vote, the Board of Directors, acting through the Audit Committee, to set the auditor’s remuneration;
3.Approving, on an advisory basis, the Company’s executive compensation;
4.Renewing the Board of Directors’ authority to issue shares under Irish law;
5.Renewing the Board of Directors’ authority to opt out of pre-emption rights under Irish law;
6.Authorizing the Company and any subsidiary of the Company to make overseas market purchases of Medtronic ordinary shares;
7.Receiving and considering the Company’s Irish Statutory Financial Statements for the fiscal year ended April 24, 2020 and the reports of the directors and auditors thereon, and reviewing the affairs of the Company;
8.Transacting any other business that may properly come before the meeting.
|
| 2020-03-06 |
除权日：
美东时间 2020-03-26 每股派息0.54美元
|
| 2019-12-06 |
除权日：
美东时间 2019-12-26 每股派息0.54美元
|
| 2019-08-23 |
除权日：
美东时间 2019-09-26 每股派息0.54美元
|
| 2019-08-16 |
股东大会：
将于2019-12-06召开股东大会
会议内容 ▼▲
- 1.Electing, by separate resolutions, the eleven director nominees named in the proxy statement to hold office until the 2020 Annual General Meeting of the Company;
2.Ratifying, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the Company’s independent auditor for fiscal year 2020 and authorizing, in a binding vote, the Board of Directors, acting through the Audit Committee, to set the auditor’s remuneration;
3.Approving, on an advisory basis, the Company’s executive compensation;
4.Renewing the Board of Directors’ authority to issue shares under Irish law;
5.Renewing the Board of Directors’ authority to opt out of pre-emption rights under Irish law;
6.Authorizing the Company and any subsidiary of the Company to make overseas market purchases of Medtronic ordinary shares;
7.Receiving and considering the Company’s Irish Statutory Financial Statements for the fiscal year ended April 26, 2019 and the reports of the directors and auditors thereon, and reviewing the affairs of the Company;
8.Transacting any other business that may properly come before the meeting.
|
| 2019-06-21 |
除权日：
美东时间 2019-07-05 每股派息0.54美元
|
| 2019-03-08 |
除权日：
美东时间 2019-03-21 每股派息0.50美元
|
| 2018-12-07 |
除权日：
美东时间 2018-12-27 每股派息0.50美元
|
| 2018-08-24 |
股东大会：
将于2018-12-07召开股东大会
会议内容 ▼▲
- 1.Electing, by separate resolutions, the ten director nominees named in the proxy statement to hold office until the 2019 Annual General Meeting of the Company;
2.Ratifying, in a non-binding vote, the re-appointment of ricewaterhouseCoopers LLP as the Company’s independent auditor for fiscal year 2019 and authorizing, in a binding vote, the Board of Directors, acting through the Audit Committee, to set the auditor’s remuneration;
3.Approving, on an advisory basis, the Company’s executive compensation;
4.Receiving and considering the Company’s Irish Statutory Financial Statements for the fiscal year ended April 27, 2018 and the reports of the directors and auditors thereon, and reviewing the affairs of the Company;
5.Transacting any other business that may properly come before the meeting.
|
| 2018-08-24 |
除权日：
美东时间 2018-09-27 每股派息0.50美元
|
| 2018-06-22 |
除权日：
美东时间 2018-07-05 每股派息0.50美元
|
| 2018-03-09 |
除权日：
美东时间 2018-03-22 每股派息0.46美元
|
| 2017-12-08 |
除权日：
美东时间 2017-12-28 每股派息0.46美元
|
| 2017-08-28 |
股东大会：
将于2017-12-08召开股东大会
会议内容 ▼▲
- 1.Electing, by separate resolutions, the twelve director nominees named in the proxy statement to hold office until the 2018 Annual General Meeting of the Company;
2.Ratifying, in a non-binding vote, the re-appointment of PricewaterhouseCoopers LLP as the Company’s independent auditor for Fiscal Year 2018 and authorizing, in a binding vote, the Board of Directors, acting through the Audit Committee, to set the auditor’s remuneration;
3.Approving on an advisory basis, the Company’s executive compensation;
4.Amending and restating the Medtronic plc Amended and Restated 2013 Stock Award and Incentive Plan;
5.Receiving and considering the Company’s Irish Statutory Financial Statements for the fiscal year ended April 28, 2017 and the reports of the directors and auditors thereon, and reviewing the affairs of the Company;
6.Transacting any other business that may properly come before the meeting.
|
| 2017-08-25 |
除权日：
美东时间 2017-09-28 每股派息0.46美元
|
| 2017-06-23 |
除权日：
美东时间 2017-07-05 每股派息0.46美元
|
| 2017-03-10 |
除权日：
美东时间 2017-03-22 每股派息0.43美元
|
| 2016-12-09 |
除权日：
美东时间 2016-12-21 每股派息0.43美元
|
| 2016-08-19 |
除权日：
美东时间 2016-09-27 每股派息0.43美元
|
| 2016-08-10 |
股东大会：
将于2016-12-09召开股东大会
会议内容 ▼▲
- 1.Electing, by separate resolutions, the 13 director nominees named in the proxy statement to hold office until the 2017 Annual General Meeting of the Company;
2.Ratifying the re-appointment of PricewaterhouseCoopers LLP as the Company’s independent auditor for fiscal year 2017 and authorizing the Board of Directors, acting through the Audit Committee, to set its remuneration;
3.Advisory approval of the Company’s executive compensation;
4.Amend the Company’s Articles of Association to Implement “Proxy Access”;
5.Amend the Company’s
5A. Articles of Association to Make Certain Administrative Amendments;
5B. Memorandum of Association to Make Certain Administrative Amendments;
6.Amend the Company’s Articles of Association to clarify the Board’s sole authority to determine its size within the fixed limits in the Articles of Association;
7.To receive and consider the Company’s Irish Statutory Financial Statements for the fiscal year ended April 29, 2016 and the reports of the directors and auditors thereon and to review the affairs of the Company;
8.Transacting any other business that may properly come before the meeting.
|
| 2016-06-24 |
除权日：
美东时间 2016-07-06 每股派息0.43美元
|
| 2016-02-19 |
除权日：
美东时间 2016-03-22 每股派息0.38美元
|
| 2016-01-12 |
复牌提示：
2016-01-11 12:23:02 停牌，复牌日期 2016-01-11 12:40:17
|
| 2015-12-11 |
除权日：
美东时间 2015-12-22 每股派息0.38美元
|
| 2015-08-21 |
除权日：
美东时间 2015-09-23 每股派息0.38美元
|
| 2015-06-19 |
除权日：
美东时间 2015-06-25 每股派息0.38美元
|
| 2015-02-13 |
除权日：
美东时间 2015-03-26 每股派息0.31美元
|